Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis
Arthritis Care and Research , 01/05/09
Albers HM et al. – In children with juvenile idiopathic arthritis (JIA), an earlier start of methotrexate (MTX) treatment leads to an increased response.
Methods- Aim was to identify of clinical and genetic factors that influence the response to MTX in JIA pts (n=128)
- 11 clinical parameters and genotypes of 6 SNPs in 5 genes related to the mechanism of action of MTX compared between MTX responders and nonresponders
- Time from diagnosis to start of MTX treatment, physician's global assessment at baseline, and the starting dose were associated with the response to MTX at 6 mo after initiation
- Pts with a shorter time from diagnosis to start of MTX and a higher disease activity with a lower MTX dose showed an increased response
- Effect of starting dose on MTX response was mainly due to the influence of systemic JIA subtype
- The time from diagnosis to start of MTX treatment and physician's global assessment at baseline were highly correlated
- Therefore, the precise effect size of each independent variable could not be determined
Today in Orthopedic/Physical Med...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Sponsor
Article Search
Sponsor
Sponsor